BeOne Medicines terminates CMB credit facility after refinancing with new facilities agreement

BeOne Medicines Ltd.

On Dec 16, 2025, used proceeds from Nov 2025 Facilities Agreement to fully repay CMB Credit Facility dated Dec 9, 2024.
All lender commitments, guarantees and security interests under CMB Credit Facility terminated.
No termination penalties incurred from the CMB Credit Facility termination.
The new Facilities Agreement involved HSBC as global coordinator and a syndicate of lenders.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

BeOne Medicines Ltd. terminated CMB Credit Facility with China Merchants Bank Co., Ltd. valued at Repaid in full all outstanding amounts, terminated all commitments and guarantees, no termination pe (effective 2025-12-16).

Action: termination
Agreement: credit facility
Counterparty: China Merchants Bank Co., Ltd.
Value: Repaid in full all outstanding amounts, terminated all commitments and guarantees, no termination pe
Effective: 2025-12-16

Exact text from the filing

On December 16, 2025, the Company utilized a portion of the proceeds from borrowings under the Facilities Agreement to repay in full all outstanding amounts owed under the Company’s Facility Agreement, dated as of December 9, 2024, by and between the Company and China Merchants Bank Co., Ltd. (the “CMB Credit Facility”), and terminated all commitments by the lender to extend further credit under the CMB Credit Facility and all guarantees and security interests granted by the Company to the lender under the CMB Credit Facility.

View on SEC.gov

Browse all material agreements →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-25-000153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.